HistoSonics Targets Interventional Oncologists With Edison Histotripsy System Showcase at SIO Conference

According to a recent LinkedIn post from HistoSonics, the company plans to engage with clinicians and industry stakeholders at the upcoming Society of Interventional Oncology (SIO) conference in Savannah, GA, scheduled for February 4–8. The post highlights a Breakfast Symposium titled “Histotripsy in Practice: Real-World Experience, Evidence, and Future Frontiers,” set for Saturday, February 7, featuring Paul Laeseke, MD, an interventional radiologist from the University of Wisconsin. The session is positioned as focusing on the progression of histotripsy from innovation toward clinical implementation.

The post also indicates that HistoSonics representatives will be available at booth #500 to discuss the company’s Edison Histotripsy System, while noting that use of the system outside liver applications is currently limited to clinical investigations. For investors, this outreach may signal ongoing efforts to build clinical awareness, gather practitioner feedback, and support adoption of histotripsy-based therapies within the interventional oncology community. Increased engagement with key opinion leaders and exposure at a specialized conference could contribute to long-term demand generation and help clarify the technology’s real-world utility and evidence base. At the same time, the disclaimer underscores that broader commercial use remains constrained by regulatory and clinical-development milestones, which are likely to remain critical determinants of the company’s future revenue trajectory and competitive positioning in minimally invasive oncology treatments.